Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Anti-Infective R&D Ecosystem Getting Healthier, But Trials Remain

Executive Summary

FDA and other government agencies have successfully nurtured a healthy ecosystem to rebuild the antibiotics pipeline, and a new crop of antibiotics has now reached the pivotal stage of clinical trials. But the sponsors are largely small companies: can they survive in the highly constrained commercial market for serious infections?

Advertisement

Related Content

Infectious Disease Companies Catch More Investors
AZ Spins Out Entasis To Tackle Resistant Infections

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register